NCT07016841View on ClinicalTrials.gov

Effects of pHA Hemoperfusion Plus Hemodialysis on Protein-Bound Uremic Toxins

RecruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

May 12, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
End Stage Renal Disease on Dialysis
Interventions
DEVICE

pHA130 hemoperfusion device

HP once every 2 weeks.

DEVICE

HD/HDF

HD twice weekly, HDF once weekly, with each session lasting 4 hours.

DEVICE

HA130 hemoperfusion device

HP once every 2 weeks.

Trial Locations (1)

200092

RECRUITING

Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER